Shilpa Biologicals Private Limited, a wholly-owned subsidiary of Shilpa Medicare Limited, in collaboration with Switzerland-based mAbTree Biologics AG, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to their investigational biologic product. The designation covers a novel, first-in-class immunology-driven monoclonal antibody being developed for the treatment of Essential Thrombocythemia (ET) and Polycythemia Vera (PV), two rare chronic blood cancers classified as myeloproliferative neoplasms (MPNs).
This regulatory milestone underscores the FDA’s recognition of the significant unmet medical need in treating these rare hematological malignancies and validates the therapeutic potential of this innovative biologic asset. The Orphan Drug Designation confers substantial regulatory and commercial advantages, including eligibility for seven years of market exclusivity upon approval, exemption from FDA user fees exceeding $4.3 million, tax credits up to 25% on qualified clinical trial expenses, and dedicated regulatory support throughout the development process.
Addressing Critical Unmet Needs in Rare Blood Cancers Treatment
Essential Thrombocythemia and Polycythemia Vera are rare, chronic blood cancers characterized by the overproduction of blood cells in the bone marrow due to mutations in genes such as JAK2. These myeloproliferative neoplasms affect approximately 7.9 per 100,000 individuals collectively, with incidence rates ranging from 1.3 to 2.8 per 100,000 population per year.
Both conditions carry substantial morbidity and mortality risks, primarily driven by thrombotic complications. Current therapeutic approaches focus predominantly on symptomatic management rather than disease modification, leaving patients with limited options for durable disease control. The investigational monoclonal antibody represents a paradigm shift by targeting the underlying immune dysregulation that drives MPN pathology, potentially offering disease-modifying benefits beyond mere symptom relief.
Differentiated Mechanism Targeting Immune Evasion Pathway
The investigational biologic is designed to target a previously underexplored immune-evasion pathway implicated in myeloproliferative neoplasm biology. By addressing immune dysregulation at its source, the therapy aims to provide durable disease control for patients with Essential Thrombocythemia and Polycythemia Vera. This immunology-driven approach distinguishes the candidate from existing therapies and positions it as a potentially transformative treatment option in the rare disease space.
The monoclonal antibody’s mechanism of action focuses on restoring appropriate immune surveillance and eliminating malignant clonal expansion, offering the possibility of converting these chronic conditions into more manageable diseases with improved long-term outcomes for patients.
Strategic Collaboration Combines Complementary Expertise
The partnership between Shilpa Biologicals and mAbTree Biologics AG leverages the complementary strengths of both organizations. Shilpa Biologicals brings deep expertise in biologics discovery, development, and GMP manufacturing through its state-of-the-art facility in Dharwad, Karnataka, India. mAbTree Biologics AG contributes specialized capabilities in advanced immunology-driven biologics and novel checkpoint modulation platforms.
Dr. Sridevi Khambhampaty, Chief Executive Officer of Shilpa Biologicals, commented on the achievement: “This FDA Orphan Drug Designation validates our strategic collaboration with mAbTree Biologics and reinforces our scientific capabilities in developing innovative biologics for unmet medical needs. This investigational therapy holds promise not only for rare blood cancers but potentially for broader applications in oncology and immunology. We remain committed to advancing this program through clinical development to bring meaningful therapeutic options to patients suffering from these challenging conditions.”
Raj Andhuvan, Chief Executive Officer of mAbTree Biologics AG, added: “The FDA’s Orphan Drug Designation represents a strong endorsement of our biologic’s differentiated mechanism targeting immune dysregulation, a key pathogenic factor in myeloproliferative neoplasms. This milestone positions our investigational therapy as a potential new standard of care for Essential Thrombocythemia and Polycythemia Vera patients who currently have limited disease-modifying treatment options. We are excited to advance this program in partnership with Shilpa Biologicals, whose manufacturing excellence and regulatory expertise will be instrumental in bringing this innovation to patients globally.”
FDA Orphan Drug Designation: Significant Regulatory and Commercial Advantages
The FDA Orphan Drug Designation is awarded to therapies targeting diseases affecting fewer than 200,000 patients in the United States. This regulatory status provides sponsors with critical incentives designed to encourage the development of treatments for rare diseases, which might otherwise be financially prohibitive.
Key benefits of the Orphan Drug Designation include:
- Seven Years of Market Exclusivity: Upon FDA approval, the sponsor receives protection against approval of competing applications for the same drug-disease combination, providing a significant commercial advantage in the rare disease market
- Tax Credits: Up to 25% tax credit on qualified U.S. clinical trial expenses, substantially reducing development costs
- Fee Exemptions: Waiver of FDA Prescription Drug User Fee Act (PDUFA) fees, valued at over $4.3 million per New Drug Application or Biologics License Application
- Regulatory Support: Enhanced FDA guidance and protocol assistance throughout the development process
- Exemption from Pediatric Studies: Relief from Pediatric Research Equity Act (PREA) requirements
These incentives significantly de-risk the development pathway and improve the commercial viability of rare disease programs, making the Orphan Drug Designation a highly coveted regulatory milestone in biopharmaceutical development.
Clinical Development Roadmap and Next Steps
Following this regulatory milestone, Shilpa Biologicals and mAbTree Biologics will advance IND-enabling studies to support the filing of an Investigational New Drug (IND) application with the FDA. These preclinical studies will generate comprehensive safety, pharmacology, and manufacturing data required to initiate clinical trials in humans.
Upon successful completion of IND-enabling studies and regulatory clearance, the partners plan to initiate first-in-human Phase I clinical trials enrolling patients with Essential Thrombocythemia and Polycythemia Vera. These early-stage trials will evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy signals of the investigational monoclonal antibody in the target patient population.
About Essential Thrombocythemia and Polycythemia Vera
Essential Thrombocythemia (ET) and Polycythemia Vera (PV) are Philadelphia chromosome-negative myeloproliferative neoplasms characterized by clonal proliferation of myeloid cells in the bone marrow. These rare blood cancers result in overproduction of blood cells—primarily platelets in ET and red blood cells in PV—leading to increased risk of thrombotic and hemorrhagic complications.
Polycythemia Vera affects approximately 44-57 per 100,000 individuals in the United States, with an annual incidence of 1.3-2.8 cases per 100,000 population. The condition occurs more frequently in males and typically manifests in individuals over 60 years of age. Essential Thrombocythemia exhibits similar epidemiological patterns with slightly lower incidence rates.
Both conditions are associated with driver mutations in JAK2, CALR, or MPL genes, with thrombosis representing the primary cause of morbidity and mortality. Current treatment paradigms focus on cytoreductive therapy, antiplatelet agents, and phlebotomy for symptom management, but disease-modifying therapies remain an area of significant unmet medical need.
Delve deeper into the evolving Myeloproliferative Neoplasms treatment landscape with DelveInsight’s latest report on Myeloproliferative Neoplasms Market Insights.
About Shilpa Biologicals Private Limited
Shilpa Biologicals Private Limited is a fully-owned subsidiary of Shilpa Medicare Limited, specializing in the discovery, development, and manufacturing of innovative biologic therapies. The company operates a state-of-the-art GMP-compliant manufacturing facility in Dharwad, Karnataka, equipped with advanced bioprocessing capabilities for monoclonal antibodies and other complex biologics.
Shilpa Biologicals has established a robust pipeline of novel biologic assets targeting oncology, immunology, and rare diseases. The company’s strategic focus encompasses both in-house innovation and collaborative partnerships with global biotechnology companies to advance next-generation therapeutics for unmet medical needs.
About mAbTree Biologics AG
mAbTree Biologics AG is a Switzerland-based biotechnology company specializing in the development of advanced immunology-driven biologics, including novel checkpoint inhibitors and monoclonal antibodies for oncology and immunological disorders. The company’s proprietary discovery platforms enable the identification of differentiated therapeutic candidates targeting previously unexploited immune pathways.
mAbTree Biologics focuses on developing first-in-class and best-in-class therapeutics that address fundamental disease mechanisms, with particular emphasis on immuno-oncology and rare diseases. Through strategic partnerships with global pharmaceutical and biotechnology companies, mAbTree aims to expand patient access to innovative medicines across diverse markets.
